In gliomas, IDH mutation-associated abnormal changes in cancer cell metabolism, gene expression profile and chromatin structure can lead to disruptions in normal epigenetic programming and, ultimately, resistance to therapy. This evidence concerns the gene IDH1 and central nervous system cancer.